Hormone boost then radiation: new hope for tough prostate cancer?
NCT ID NCT07476001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new two-step approach for men with advanced prostate cancer that has stopped responding to standard hormone therapy. First, patients receive a high dose of testosterone, followed by a targeted radioactive drug. The goal is to see if this combination is safe and can shrink the cancer. About 12 men will take part for roughly 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can targeted radiation tame advanced prostate cancer? a registry aims to find out